STUDY OBJECTIVES Parkinson's disease (PD) causes significant socioeconomic burdens. One of the strongest predictors of PD is REM sleep behavior disorder (RBD) (when there is no known other cause of RBD, referred to as idiopathic RBD), but there is no information about its factual welfare burden. We estimated the direct and indirect total costs of iRBD in a national sample of patients, based on a national register-based cohort study with matched controls. METHODS Using records from the Danish National Patient Registry, patient's diagnosis with RBD from 2006 to 2016 were identified. We excluded patients with a prior diagnosis of narcolepsy, Parkinson's disease and other neurodegenerative diseases. We identified and compared randomly chosen controls matched for age, gender, geographic area and civil status. Direct costs included frequencies of primary and secondary sector contacts and procedures, and medication. Indirect costs included the effect on labor supply. Social-transfer payments were included to illustrate the effect on national accounts. RESULTS 246 iRBD patients and 982 matched controls were registered. iRBD patients had significantly higher rates of health-related contacts and of medication use, and higher socioeconomic costs than controls. The total additional direct net healthcare costs after the diagnosis (general practitioner services, hospital services, and medication) and indirect costs (loss of labor market income) was €13,088 for patients compared with controls. Patients already exhibited a negative social- and health-related status several years before the first diagnosis. CONCLUSIONS Diagnoses of iRBD have major socioeconomic consequences for patients, their partners and society.

中文翻译：

---

REM 睡眠行为障碍的健康、社会和经济后果：一项评估社会影响的受控国家研究

研究目标 帕金森病 (PD) 会造成重大的社会经济负担。PD 的最强预测因素之一是 REM 睡眠行为障碍 (RBD)（当没有已知的其他 RBD 原因时，称为特发性 RBD），但没有关于其实际福利负担的信息。我们根据具有匹配对照的全国登记队列研究，估计了全国患者样本中 iRBD 的直接和间接总成本。方法使用丹麦国家患者登记处的记录，确定了 2006 年至 2016 年患者的 RBD 诊断。我们排除了先前诊断为发作性睡病、帕金森病和其他神经退行性疾病的患者。我们确定并比较了随机选择的与年龄、性别、地理区域和公民身份相匹配的对照。直接成本包括初级和次级部门接触和程序的频率以及药物。间接成本包括对劳动力供应的影响。包括社会转移支付以说明对国民账户的影响。结果 登记了 246 名 iRBD 患者和 982 名匹配的对照。与对照组相比，iRBD 患者的健康相关接触率和药物使用率显着更高，社会经济成本也更高。与对照组相比，患者在诊断后（全科医生服务、医院服务和药物治疗）和间接成本（劳动力市场收入损失）的额外直接净医疗保健费用总额为 13,088 欧元。在首次诊断前几年，患者已经表现出与社会和健康相关的负面状态。